PDCD1 and neoplasm: While they did find a synergistic anti-tumor effect by combining Lm-LLO-E7 with anti-PD-1 antibody, the dosage of Lm-LLO-E7 was approximately 5-fold lower and less effective than previous studies which may have better revealed the synergistic effect of these two therapeutics (110).